作者
Susan Tsai, Ben George, David Wittmann, Paul S Ritch, Ashley N Krepline, Mohammed Aldakkak, Chad A Barnes, Kathleen K Christians, Kulwinder Dua, Michael Griffin, Catherine Hagen, William A Hall, Beth A Erickson, Douglas B Evans
发表日期
2020/4/1
期刊
Annals of surgery
卷号
271
期号
4
页码范围
740-747
出版商
LWW
简介
Objective:
Carbohydrate antigen 19-9 (CA19-9) is a prognostic marker for patients with pancreatic cancer (PC), but its value as a treatment biomarker is unclear.
Summary Background Data:
Although CA19-9 is an established prognostic marker for patients with PC, it is unclear how CA19-9 monitoring should be used to guide multimodality treatment and what level of change in CA19-9 constitutes a meaningful treatment response.
Methods:
CA19-9 measurements at diagnosis (pretx), after completion of all planned neoadjuvant therapy (preop), and after surgery (postop) were analyzed in patients with localized PC who had an elevated CA19-9 (≥ 35 U/dL) at diagnosis. Patients were classified by: 1) quartiles of pretx CA19-9 (Q1-4); 2) proportional changes in CA19-9 (ΔCA19-9) after the completion of neoadjuvant therapy; 3) normalization (CA19-9< 35 U/dL) of preop CA19-9; and 4) normalization of postop CA19-9 …
学术搜索中的文章
S Tsai, B George, D Wittmann, PS Ritch, AN Krepline… - Annals of surgery, 2020